Sinew Pharma Inc.
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also… Read more
Sinew Pharma Inc. (6634) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.044x
Based on the latest financial reports, Sinew Pharma Inc. (6634) has a cash flow conversion efficiency ratio of -0.044x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-50.66 Million) by net assets (NT$1.15 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sinew Pharma Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Sinew Pharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sinew Pharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinew Pharma Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Afya Limited
SA:A2FY34
|
0.269x |
|
Khon Kaen Sugar Industry PCL
BK:KSL
|
0.075x |
|
TITANIUM TRANSPORT.GROUP
F:I9V
|
N/A |
|
Altinyag Kombinalari AS
IS:ALMAD
|
0.013x |
|
ANPAC BIO-MED SP.ADS/20 A
F:0UC0
|
N/A |
|
ICD Co. Ltd
KQ:040910
|
-0.061x |
|
Horizon Space Acquisition II Corp. Units
NASDAQ:HSPTU
|
-0.004x |
|
WIELTON S.A. ZY-20
F:2W1
|
N/A |
Annual Cash Flow Conversion Efficiency for Sinew Pharma Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Sinew Pharma Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.20 Billion | NT$-106.08 Million | -0.089x | +0.65% |
| 2023-12-31 | NT$1.32 Billion | NT$-118.05 Million | -0.089x | -38.73% |
| 2022-12-31 | NT$1.46 Billion | NT$-93.76 Million | -0.064x | -75.95% |
| 2021-12-31 | NT$1.57 Billion | NT$-57.32 Million | -0.037x | +73.14% |
| 2020-12-31 | NT$435.76 Million | NT$-59.26 Million | -0.136x | +60.92% |
| 2019-12-31 | NT$168.77 Million | NT$-58.73 Million | -0.348x | -- |